

Human CellExp™ BAFF, Mouse Recombinant

CATALOG NO:	P1370-10	10 µg
ALTERNATE NAMES:	TNFSF13B, BAFF, BLYS, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, ZTNF4	
SOURCE:	HEK 293 cells (Ala 127 - Leu 309)	
PURITY:	> 90% by SDS – PAGE	
MOL. WEIGHT:	This protein carries no "tag". The protein has a calculated MW of 20.9 kDa. The protein migrates as 20 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.	
ENDOTOXIN LEVEL:	< 1.0 EU per 1µg of protein (determined by LAL method)	
FORM:	Lyophilized	
FORMULATION:	Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.	
STORAGE CONDITIONS:	Store at -20°C. After reconstitution, aliquot and store at -80°C and use within 3 months. Avoid repeated freezing and thawing cycles.	
RECONSTITUTION:	Centrifuge the vial prior to opening. Reconstitute in sterile deionized water to a concentration of 50 µg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% (W/V) HSA or BSA) is recommended for further dilution and long term storage. Do not vortex.	
DESCRIPTION:	B-cell activating factor (BAFF) is also known as tumor necrosis factor ligand superfamily member 13B , TNFSF13B, BAFF, B Lymphocyte Stimulator (BLyS) , cluster of differentiation 257 (CD257), DTL, TNF- and APOL-related leukocyte expressed ligand (TALL-1), THANK, TNFSF20, ZTNF4, and is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. It is expressed as transmembrane protein on various cell types including monocytes, dendritic cells and bone marrow stromal cells. BAFF is the natural ligand of three unusual tumor necrosis factor receptors named BAFF-R, TACI, and BCMA, all of which have differing binding affinities for it. These receptors are expressed mainly on mature B lymphocytes (TACI is also found on a subset of T-cells and BCMA on plasma cells). TACI binds worst since its affinity is higher for a protein similar to BAFF, called a proliferation-inducing ligand (APRIL). BCMA displays an intermediate binding phenotype and	

will work with either BAFF or APRIL to varying degrees. Signaling through BAFF-R and BCMA stimulates B lymphocytes to undergo proliferation and to counter apoptosis. All these ligands act as heterotrimers (i.e. three of the same molecule) interacting with heterotrimeric receptors, although BAFF has been known to be active as either a hetero- or homotrimer. BAFF acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells.

SPECIFIC ACTIVITY:

Immobilized Mouse BAFF at 2 µg/mL (100 µL/well) can bind Mouse BAFFR, Fc Tag with a linear range of 0.4-3 ng/mL




Fig. A. Mouse BAFF, Tag Free on SDS-PAGE under reducing (R) condition.

Fig. B. Immobilized Mouse BAFF at 2 µg/mL (100 µL/well) can bind Mouse BAFFR, Fc Tag with a linear range of 0.4-3 ng/mL

RELATED PRODUCT:

- Human CellExp™ BAFF, human recombinant (**Cat. No. 7222**)
- Human CellExp™ BAFFR/TNFRSF13C, FcTag Human Recombinant (**Cat. No. P1170**)
- BAFF Receptor, human recombinant (**Cat. No. 4452**)
- BAFF, human recombinant (**Cat. No. 4451**)
- BAFF, rat recombinant (**Cat. No. 4453**)
- BAFF Antibody (**Cat. No. 3203**)
- BAFF-R Polyclonal Antibody (**Cat. No. 3578**)

FOR RESEARCH USE ONLY! Not to be used on humans.